A Novel Ocular Fibrosis Signature for AMD Using the Two-Stage Laser-Induced Subretinal Fibrosis Mouse Model
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.10.49 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by David Hughes and 8 co-authors. Institution: The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom. Major MEDLINE topics: Retinal Pigment Epithelium, Macular Degeneration. 68 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Subretinal fibrosis is a major cause of irreversible vision loss in neovascular age-related macular degeneration (AMD), yet no effective antifibrotic therapies exist due to poorly defined molecular drivers. This study aimed to derive and validate a persistent ocular fibrosis signature using the two-stage laser-induced subretinal fibrosis mouse model and to assess its translational relevance in human AMD.
Methods
RNA sequencing (RNA-seq) was performed on retinal pigment epithelium (RPE)/choroid tissues collected at days 3, 6, and 10 following the second laser injury in the two-stage model. A novel core fibrosis signature of 88 persistently upregulated genes was observed across all time points and cross-validated in an independent mouse dataset (GSE189555) and multiple human AMD RNA-seq datasets (GSE115828, GSE146887, GSE135092), including surgically extracted choroidal neovascularization (CNV) membranes and macular RPE/choroid samples. Key signature genes were further validated by immunofluorescence in human subretinal fibrotic and age-matched tissues.
Results
The novel ocular fibrosis signature was enriched in epithelial-mesenchymal transition, complement activation, and inflammatory pathways and showed choroid-specific expression with minimal retinal involvement. Cross-validation on independent chronic mouse data and multiple human AMD datasets (peripheral retina, surgically extracted CNV membranes, and macular RPE/choroid) confirmed a progressive enrichment in advanced disease stages. Immunofluorescence in human fibrotic tissue validated key genes (tenascin C, tissue inhibitor of metalloproteinases 1, and apelin receptor) and showed colocalization with myofibroblast-like cells and microglia.
Conclusions
We identified a novel, persistent, choroid-specific ocular fibrosis signature with strong cross-species conservation, highlighting fibrogenic-associated drivers and providing a valuable translational tool to understand subretinal fibrosis development and targeted antifibrotic therapies in neovascular AMD.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
- Johnston Cancer Research Centre, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach Riss, Germany.
Cite
APA
Hughes, D., Larue, A. E. M., Taus, P., Markert, E., Bhattacharyya, D., Atlasi, Y., Neubauer, H., Xu, H., & Chen, M. (2026). A Novel Ocular Fibrosis Signature for AMD Using the Two-Stage Laser-Induced Subretinal Fibrosis Mouse Model. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.10.49
Vancouver
Hughes D, Larue AEM, Taus P, Markert E, Bhattacharyya D, Atlasi Y, et al. A Novel Ocular Fibrosis Signature for AMD Using the Two-Stage Laser-Induced Subretinal Fibrosis Mouse Model. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.10.49
BibTeX
@article{Hughes2026,
author = {Hughes, David and Larue, Axelle E M and Taus, Petr and Markert, Elke and Bhattacharyya, Diya and Atlasi, Yaser and Neubauer, Heike and Xu, Heping and Chen, Mei},
title = {A Novel Ocular Fibrosis Signature for AMD Using the Two-Stage Laser-Induced Subretinal Fibrosis Mouse Model},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.10.49}
}
EUVIMED